1813-24-7 Usage
General Description
5-Methyl-2-nitro-4-trifluoromethyl-phenylamine, also known as MNTFM-Phenylamine, is a chemical compound with the molecular formula C7H6F3N2O2. It is a derivative of aniline and is often used in chemical research and pharmaceutical development. 5-Methyl-2-nitro-4-trifluoromethyl-phenylamine is characterized by the presence of a trifluoromethyl group, a nitro group, and a methyl group attached to a phenyl ring. MNTFM-Phenylamine has potential applications in the synthesis of various organic compounds and may also be of interest in areas such as medicinal chemistry and materials science. However, as with any chemical compound, proper handling and safety precautions should be observed when working with MNTFM-Phenylamine to minimize the risk of adverse effects.
Check Digit Verification of cas no
The CAS Registry Mumber 1813-24-7 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,8,1 and 3 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1813-24:
(6*1)+(5*8)+(4*1)+(3*3)+(2*2)+(1*4)=67
67 % 10 = 7
So 1813-24-7 is a valid CAS Registry Number.
1813-24-7Relevant articles and documents
Novel compounds as metabotropic glutamate receptor antagonists
-
Page/Page column 10-11, (2008/06/13)
The present invention relates to compounds of formula (I) wherein A, E G, J, L, M, R1, R2, and R3 are as defined in the specification and claims. The invention also relates to pharmaceutical compositions containing such compounds and methods for preparing the compounds and compositions. The compounds are metabotropic glutamate receptor antagonists and are useful for the treatment of a variety of CNS disorders.
Acetylenyl-pyrazolo-pyrimidine derivatives
-
Page/Page column 22, (2008/06/13)
The present invention relates to compounds of formula (I): wherein R1 to R3, A, M, L, E, G, and J are as defined in the description and claims. The invention also relates to a process for the manufacture of such compounds, pharmaceutical compositions containing them, and methods for treating CNS disorders.
